MA-ECHOSENS
21.6.2022 14:58:10 CEST | Business Wire | Press release
Echosens , a high-technology company offering the FibroScan® portfolio of solutions, is pleased to announce its solutions will be included in 22 oral presentations and 157 posters that will evaluate utilization of the non-invasive FibroScan® tool across a variety of liver disease etiologies and practice settings at EASL International Liver Congress™ 2022, June 22-26, 2022, London, United Kingdom. Echosens leaders will present the symposium “FibroScan® Solutions Bringing New Guidelines to Life,” 11 a.m.-12:30 p.m., Meeting Room N19, ExCel London Center, on June 23. Additionally, Echosens will offer “How to Improve Early Screening and Management of Chronic Liver Disease Outside Hospital Setting?” -- two demonstrations of FibroScan® GO, 3 p.m.-4 p.m. or 5:30 p.m.-6:30 p.m. on June 23 in Meeting Room N19, ExCel London.
“This very important meeting furthers the worldwide understanding of liver research, enhances the clinical practice of liver disorders and educates those interested in hepatology,” says Dominique Legros, Group CEO, Echosens. “FibroScan® , the non-invasive solution for comprehensive management of liver health, is recognized worldwide, validated by over 3,500 peer reviewed publications and 160 international guidelines and considered the most widely studied tool for point of care liver assessment.”
Echosens will be available at booth N°46 to discuss and demonstrate early detection with new FibroScan GO, diagnosing and monitoring with FibroScan Mini+ 430 and FibroScan Compact 530, advanced diagnosis and risk stratification with FibroScan Expert 630 live patient demonstration, and digital demonstrations of myFibroScan and Scores by Echosens.
Jon Gingrich, CEO, Echosens North America, adds, “We are thrilled by the global validation of FibroScan and broad consensus of the need for screening and early intervention to prevent advanced liver disease. FibroScan can more cost-effectively identify individuals who are asymptomatic and undiagnosed for liver damage, as well as provide metrics for monitoring changes in liver fat due to lifestyle modification.”
About Echosens
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan® , the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 3,500 peer reviewed publications and 160 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005114/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SAP strengthens its cloud infrastructure in Germany with BSI-approved Layer 1 encryption from Adva Network Security19.8.2026 09:00:00 CEST | Press release
News summary: SAP needed to secure connectivity between its German data centers to meet strict confidentiality, compliance and data control requirements BSI-approved Layer 1 encryption from Adva Network Security enables SAP to protect all data streams and future-proof its infrastructure against quantum threats Solution strengthens sovereign cloud foundations for government, critical infrastructure and regulated industries with high security and compliance needs Adva Network Security, an Adtran company, today announced that SAP is harnessing its Layer 1 encryption technology to secure connectivity between its data centers in Walldorf and St. Leon-Rot, Germany. The solution secures data directly at the optical transmission layer and is approved by the Federal Office for Information Security (BSI) for information classified up to “Verschlusssache – Nur für den Dienstgebrauch” (VS-NfD) – “For Official Use Only.” By strengthening the protection of data in transit, SAP is enhancing the secur
Qatar to Showcase Its Gaming Ambitions at Gamescom 202619.8.2026 09:00:00 CEST | Press release
Invest Qatar, the country’s Investment Promotion Agency, and Media City Qatar will participate at Gamescom 2026 through the “Qatar Pavilion”, highlighting Qatar’s growing role as a regional hub for game development, digital content and esports. Held annually in Cologne, Germany, Gamescom, a leading global event, brings together developers, publishers, investors and creators. Qatar’s participation reflects its focus on building a competitive, innovation-led ecosystem for gaming and interactive media. Mohammed Al Mulla, Head of Investment Development, Invest Qatar, said: “Gamescom provides a key platform to connect with global gaming leaders and highlight emerging opportunities across Qatar and the wider Middle East. We are focused on enabling companies to enter and scale in a high-growth market through a business environment designed for innovation and long-term success.” Dr. Fahad Abdulla Al Hajri, Business Development Manager, Media City Qatar, said: "Gaming is becoming one of the def
IFF to Webcast Fireside Chat at Barclays Global Consumer Conference on Sept. 1018.8.2026 22:15:00 CEST | Press release
IFF (NYSE: IFF) today announced that Chief Executive Officer Erik Fyrwald will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, Sept. 10, 2026 at 945 a.m. ET. Investors may access the live webcast on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, and health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20260818490253/en/
Lehman Brothers Treasury Announces the Successful Sale of its Remaining Intercompany Claim against Lehman Brothers Holdings Inc.18.8.2026 21:15:00 CEST | Press release
In connection with its previously announced final wind-down, Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”), through its U.S. counsel Herbert Smith Freehills Kramer (US) LLP, announced that its placement agent, Seaport Loan Products LLC, successfully closed the sale of LBT’s remaining $19.6 billion Class 4A intercompany claim against Lehman Brothers Holdings Inc. The net proceeds of the sale, together with certain available cash (but after deducting various sale-related and other administrative costs and expenses), will be used to fund a final distribution to the holders of LBT’s existing notes, after which such existing notes will be canceled and LBT shall be fully wound down. As a result, LBT will cease to exist. LBT expects the final distribution to occur in the course of October 2026 and the wind down to have been completed before the end of 2026. View source version on businesswire.com: https://www.businesswire.com/news/home/20260818004215/en/
GenBio AI Builds First World Model of the Human Cell18.8.2026 15:00:00 CEST | Press release
First-of-its-kind system simulates human cell behavior across the full biological hierarchy, from DNA and RNA through protein to the whole-cell level GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions. Today, the company introduced AIDO Cell, its virtual cell world model — the first system capable of simulating a human cell, both in its natural state and in response to drugs and other interventions, across its full biological hierarchy, from DNA and RNA through protein to the whole-cell level. A Key First in Biological and Medical Sciences: Full-hierarchy virtual cell simulation has been widely identified as a key milestone in computational biology. Compared to the previous efforts by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom